Jumpei Takeshita

Suggest Changes
Learn More
OBJECTIVE Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line chemotherapy in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). The aim of this(More)